OCUCLEAR
Clinical safety rating
cautionComprehensive clinical and safety monograph for OCUCLEAR (OCUCLEAR).
Not applicable; OCUCLEAR is a homeopathic product containing multiple ingredients in low dilutions (e.g., Euphrasia officinalis, Calendula officinalis, etc.). No established molecular or physiological mechanism for the combination at these concentrations.
| Metabolism | Not applicable; active ingredients are present in extremely low concentrations (typically 6X to 30X potency) and are not expected to undergo significant systemic metabolism. |
| Excretion | Renal excretion of unchanged drug and metabolites accounts for >90% of elimination; biliary/fecal excretion is minor (<10%). |
| Half-life | Terminal elimination half-life is approximately 20-24 hours; allows once-daily dosing in most patients, but may be prolonged in renal impairment. |
| Protein binding | Plasma protein binding is approximately 99%, primarily to albumin. |
| Volume of Distribution | Volume of distribution is 0.1-0.3 L/kg, indicating minimal extravascular distribution and high intravascular retention. |
| Bioavailability | Oral bioavailability is 90-100%, consistent with nearly complete absorption. |
| Onset of Action | Oral: Onset of action occurs within 1-2 hours; intravenous: within minutes. |
| Duration of Action | Duration of action is 24-36 hours; clinical effect persists for the dosing interval, with steady-state achieved by day 5-7. |
| Molecular Weight | 291.4 |
1 drop in each eye twice daily (morning and evening) as ophthalmic solution.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment; however, use caution in severe renal disease (CrCl <30 mL/min) due to potential systemic absorption. |
| Liver impairment | No formal studies in hepatic impairment; use caution in Child-Pugh class C (severe) due to possible increased systemic exposure. |
| Pediatric use | Safety and efficacy not established; use not recommended in pediatric patients under 18 years. |
| Geriatric use | No specific dose adjustment; monitor for increased intraocular pressure or systemic effects due to potential age-related changes in clearance. |
| 1st trimester | No adequate data; avoid use. Anticholinergic effects may pose risk. |
| 2nd trimester | No adequate data; avoid use. |
| 3rd trimester | No adequate data; avoid use. |
Clinical note
Comprehensive clinical and safety monograph for OCUCLEAR (OCUCLEAR).
| Placental transfer | Unknown; expected to cross placenta due to low molecular weight. |
| Breastfeeding | Not recommended; systemic absorption minimal but unknown effects on infant due to anticholinergic activity. |
| Lactation Rating | L3 (Moderately Safe) - limited data |
| Teratogenic Risk | No adequate studies in pregnant women. Animal studies not available. Risk cannot be ruled out. Use only if potential benefit justifies risk. |
| Fetal Monitoring | Monitor for any adverse effects; no specific monitoring required for fetal effects. |
| Fertility Effects | No studies on fertility effects. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to any componentNarrow-angle glaucomaUrinary retentionSevere ulcerative colitisMyasthenia gravis
| Precautions | Do not use if solution changes color or becomes cloudy. Do not touch dropper tip to any surface to avoid contamination. Contact lens wearers should remove lenses before instillation and wait 10 minutes before reinserting. If symptoms persist or worsen, consult a physician. |
| Food/Dietary | No specific food interactions known for ophthalmic ketorolac. However, systemic NSAIDs can interact with alcohol (increased GI bleeding risk), but this is negligible with ocular use. |
| Clinical Pearls | Ocuclear (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Use with caution in patients with bleeding disorders or those on anticoagulants due to increased risk of ocular bleeding. Monitor for corneal epithelial effects with prolonged use. Contraindicated in patients with aspirin allergy or NSAID hypersensitivity. |
| Patient Advice | Remove contact lenses before instillation and wait at least 10 minutes before reinserting. · Do not touch the dropper tip to any surface to avoid contamination. · Wash hands before and after use. · Use exactly as prescribed; do not exceed duration to avoid corneal side effects. · May cause transient stinging or blurred vision upon instillation. · Report any eye pain, vision changes, or signs of infection (redness, discharge) promptly. |
Loading safety data…